查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612638

骨轉移市場：按治療類型、類型、最終用戶、適應症分類 - 全球預測 2025-2030

Bone Metastasis Market by Treatment Type (Medications, Therapy), Type (Mixed Bone Metastasis, Osteoblastic Bone Metastasis, Osteolytic Bone Metastasis), End-User, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年骨轉移市值為182.4億美元，預計到2024年將達到196.2億美元，複合年成長率為7.69%，到2030年將達到306.6億美元。

骨轉移是指癌細胞從原發部位擴散至骨，形成繼發性惡性。這種情況在乳癌、攝護腺癌和肺癌中很常見，由於患者疼痛、骨折和活動能力下降，給醫療保健帶來了重大挑戰。骨轉移治療市場是由全球癌症發病率不斷上升和老年人口不斷增加所推動的，而老年人口本質上更容易受到此類疾病的影響。該市場包括化療、荷爾蒙療法、標靶治療以及雙磷酸鹽和 RANK 配體抑制劑等骨標標靶治療等治療方法。最終用途包括醫院、專科診所、癌症治療中心等。

主要市場統計
基準年[2023] 182.4億美元
預測年份 [2024] 196.2億美元
預測年份 [2030] 306.6億美元
複合年成長率（%） 7.69%

該市場的關鍵成長要素包括診斷技術的進步、宣傳宣傳活動以及減少副作用和改善治療結果的新型療法的市場開拓。隨著對個人化醫療的日益關注以及用於早期檢測和監測的先進診斷成像技術的整合，機會比比皆是。此外，由於醫療保健基礎設施的改善和患者獲得創新治療的機會增加，新興市場具有成長潛力。

然而，其局限性包括治療成本上升、監管障礙以及現有治療方法的潛在副作用，從而抑制患者的依從性。癌症突變的複雜性以及對多學科治療方法的需求也帶來了挑戰，這阻礙了市場的快速成長。創新研究領域包括研究用於早期檢測的新生物標記、開發微創治療方法以及探索免疫療法在骨轉移治療中的作用。市場充滿活力，製藥公司不斷投資研發，尋求有效且有針對性的解決方案。因此，公司應優先考慮合作研究舉措，確保獲得最尖端科技，並加強全球夥伴關係關係，以解決未滿足的需求並利用成長機會。

市場動態：揭示快速發展的骨轉移市場的關鍵市場洞察

供需的動態交互作用正在改變骨轉移市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於癌症發生率上升，產品需求增加
    • 擴大臨床環境中的效用與應用
  • 市場限制因素
    • 治療費用上漲和報銷政策有限
  • 市場機會
    • 開發先進治療方法和創新藥物
    • 擴大製藥公司與研究機構之間的策略聯盟
  • 市場挑戰
    • 假藥的存在

波特的五力：駕馭骨轉移市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨轉移市場的外部影響

外部宏觀環境因素在塑造骨轉移市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解骨轉移市場的競爭格局

對骨轉移市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣骨轉移市場廠商績效評估

FPNV定位矩陣是評估骨轉移市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了骨轉移市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對骨轉移市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於癌症發生率上升，產品需求增加
      • 擴大臨床環境中的效用與應用
    • 抑制因素
      • 治療費用上漲和報銷政策有限
    • 機會
      • 開發先進的治療方法和創新藥物
      • 擴大製藥公司與研究機構之間的策略聯盟
    • 任務
      • 假藥的存在
  • 市場區隔分析
    • 類型：乳癌、肺癌和多發性骨髓瘤病例中出現溶骨性骨轉移的快速趨勢
    • 適應症：前列腺癌骨轉移的趨勢增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的骨轉移市場

  • 藥品
    • 雙磷酸鹽
    • 止痛藥
  • 治療
    • 化療
    • 放射治療
    • 手術治療

第7章骨轉移市場：依類型

  • 混合性骨轉移
  • 成骨細胞骨轉移
  • 溶骨性骨轉移

第 8 章骨轉移市場：依最終用戶分類

  • 醫院/診所
  • 研究機構。
  • 專業癌症治療中心

第9章按適應症分類的骨轉移市場

  • 乳癌
  • 肺癌
  • 攝護腺癌

第10章北美和南美骨轉移市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太骨轉移市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲骨轉移市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Denosumab生物相似藥，擴大骨相關疾病的治療選擇
    • FDA核准Medtronic增強 OsteoCool 2.0 系統用於骨腫瘤消融
    • Telix Pharmaceuticals Limited 的策略性收購利用 QSAM Biosciences, Inc. 的創新放射性藥物平台來增強骨癌的治療選擇
  • 戰略分析和建議

公司名單

  • AS Lifesciences
  • AdvaCare Pharma USA
  • Aetos Pharma Private Limited
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Beacon Pharmaceuticals PLC.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Encapsula NanoSciences LLC
  • Fresenius Kabi AG
  • Getwell Pharma India Private Limited
  • Global Calcium PVT LTD
  • GLS Pharma Pvt. Ltd.
  • LEXICARE PHARMA PVT. LTD.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd
  • Zydus Lifesciences Limited
Product Code: MRR-5D693B46C017

The Bone Metastasis Market was valued at USD 18.24 billion in 2023, expected to reach USD 19.62 billion in 2024, and is projected to grow at a CAGR of 7.69%, to USD 30.66 billion by 2030.

Bone metastasis refers to the spread of cancer cells from their original site to bones, forming secondary malignant growths. This condition is common in cancers such as breast, prostate, and lung and poses significant healthcare challenges due to pain, fractures, and reduced mobility in patients. The market for bone metastasis treatments is driven by the increasing prevalence of cancer globally and the growing geriatric population, which is inherently more susceptible to such conditions. This market encompasses therapies such as chemotherapy, hormone therapy, targeted therapy, and bone-targeted treatments like bisphosphonates and RANK ligand inhibitors. The end-use scope broadly includes hospitals, specialty clinics, and cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 18.24 billion
Estimated Year [2024] USD 19.62 billion
Forecast Year [2030] USD 30.66 billion
CAGR (%) 7.69%

Key growth factors for this market include advancements in diagnostic technologies, awareness campaigns, and the development of novel therapeutics that offer improved outcomes with reduced side effects. Opportunities abound in the increasing focus on personalized medicine and the integration of advanced imaging technologies for early detection and monitoring. Additionally, emerging markets present growth potential due to improving healthcare infrastructure and rising patient access to innovative treatments.

However, the market faces limitations such as the high cost of treatment, regulatory hurdles, and potential side effects of existing therapies that deter patient compliance. Challenges also arise from the complexity of cancer mutations and the need for multidisciplinary approaches in treatment, which can hinder swift market growth. Innovation areas include researching new biomarkers for early detection, developing minimally invasive treatment options, and exploring the role of immunotherapy in treating bone metastasis. The market is dynamic, with continuous investment in R&D by pharmaceutical companies seeking effective, targeted solutions. Therefore, businesses should prioritize collaborative research initiatives, ensure access to cutting-edge technology, and strengthen global partnerships to address unmet needs and capitalize on growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bone Metastasis Market

The Bone Metastasis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing product demand due to the rising prevalence of cancer
    • Expanded utility and application in clinical settings
  • Market Restraints
    • High cost of treatments and limited reimbursement policies
  • Market Opportunities
    • Development of sophisticated therapies and innovative medications
    • Extending strategic alliances between pharmaceutical companies and research institutions
  • Market Challenges
    • Presence of counterfeit medications

Porter's Five Forces: A Strategic Tool for Navigating the Bone Metastasis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bone Metastasis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bone Metastasis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bone Metastasis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bone Metastasis Market

A detailed market share analysis in the Bone Metastasis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bone Metastasis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bone Metastasis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bone Metastasis Market

A strategic analysis of the Bone Metastasis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bone Metastasis Market, highlighting leading vendors and their innovative profiles. These include A.S. Lifesciences, AdvaCare Pharma USA, Aetos Pharma Private Limited, Amgen Inc., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Beacon Pharmaceuticals PLC., Cipla Limited, Dr. Reddy's Laboratories Ltd., Encapsula NanoSciences LLC, Fresenius Kabi AG, Getwell Pharma India Private Limited, Global Calcium PVT LTD, GLS Pharma Pvt. Ltd., LEXICARE PHARMA PVT. LTD., Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Bone Metastasis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Therapy. The Medications is further studied across Bisphosphonates and Pain Relievers. The Therapy is further studied across Chemotherapy, Radiation Therapy, and Surgical Treatments.
  • Based on Type, market is studied across Mixed Bone Metastasis, Osteoblastic Bone Metastasis, and Osteolytic Bone Metastasis.
  • Based on End-User, market is studied across Hospitals & Clinics, Research Institutions., and Specialty Cancer Treatment Centers.
  • Based on Indication, market is studied across Breast Cancer, Lung Cancer, and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing product demand due to the rising prevalence of cancer
      • 5.1.1.2. Expanded utility and application in clinical settings
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatments and limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of sophisticated therapies and innovative medications
      • 5.1.3.2. Extending strategic alliances between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning tendency of osteolytic bone metastasis occurrence seen in cases of breast cancer, lung cancer, and multiple myeloma
    • 5.2.2. Indication: Increasing propensity of bone metastasis from prostate cancer
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bone Metastasis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bisphosphonates
    • 6.2.2. Pain Relievers
  • 6.3. Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Radiation Therapy
    • 6.3.3. Surgical Treatments

7. Bone Metastasis Market, by Type

  • 7.1. Introduction
  • 7.2. Mixed Bone Metastasis
  • 7.3. Osteoblastic Bone Metastasis
  • 7.4. Osteolytic Bone Metastasis

8. Bone Metastasis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Institutions.
  • 8.4. Specialty Cancer Treatment Centers

9. Bone Metastasis Market, by Indication

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Americas Bone Metastasis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bone Metastasis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bone Metastasis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Greenlights First Denosumab Biosimilars, Expanding Treatment Options for Bone-Related Disorders
    • 13.3.2. FDA ApprovesMedtronic PLC.'s Enhanced OsteoCool 2.0 System for Bone Tumor Ablation
    • 13.3.3. Strategic Acquisition by Telix Pharmaceuticals Limited to Enhance Bone Cancer Treatment Options with QSAM Biosciences, Inc.' Innovative Radiopharmaceutical Platform
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A.S. Lifesciences
  • 2. AdvaCare Pharma USA
  • 3. Aetos Pharma Private Limited
  • 4. Amgen Inc.
  • 5. Amneal Pharmaceuticals, Inc.
  • 6. Baxter International, Inc.
  • 7. Beacon Pharmaceuticals PLC.
  • 8. Cipla Limited
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Encapsula NanoSciences LLC
  • 11. Fresenius Kabi AG
  • 12. Getwell Pharma India Private Limited
  • 13. Global Calcium PVT LTD
  • 14. GLS Pharma Pvt. Ltd.
  • 15. LEXICARE PHARMA PVT. LTD.
  • 16. Merck & Co., Inc.
  • 17. Pfizer Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceuticals Industries Ltd
  • 20. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. BONE METASTASIS MARKET RESEARCH PROCESS
  • FIGURE 2. BONE METASTASIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BONE METASTASIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BONE METASTASIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BONE METASTASIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BONE METASTASIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BONE METASTASIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BONE METASTASIS MARKET DYNAMICS
  • TABLE 7. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BONE METASTASIS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BONE METASTASIS MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BONE METASTASIS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BONE METASTASIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BONE METASTASIS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BONE METASTASIS MARKET SIZE, BY MIXED BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOBLASTIC BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOLYTIC BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BONE METASTASIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BONE METASTASIS MARKET SIZE, BY RESEARCH INSTITUTIONS., BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BONE METASTASIS MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BONE METASTASIS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BONE METASTASIS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BONE METASTASIS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. BONE METASTASIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. BONE METASTASIS MARKET, FPNV POSITIONING MATRIX, 2023